Literature DB >> 18619857

Classification of amyloid deposits in diagnostic cardiac specimens by immunofluorescence.

A Bernard Collins1, R Neal Smith, James R Stone.   

Abstract

BACKGROUND: At least 12 distinct forms of amyloidosis are known to involve the heart or great vessels. Patient treatment regimens require proper subtyping of amyloid deposits in small diagnostic cardiac specimens. A growing lack of confidence in immunohistochemical staining for subtyping amyloid has arisen primarily as a result of studies utilizing immunoperoxidase staining of formalin-fixed paraffin-embedded tissue. Immunofluorescence staining on fresh frozen tissue is generally considered superior to immunoperoxidase staining for subtyping amyloid; however, this technique has not previously been reported in a series of cardiac specimens.
METHODS: Amyloid deposits were subtyped in 17 cardiac specimens and 23 renal specimens using an immunofluorescence panel.
RESULTS: Amyloid deposits were successfully subtyped as AL, AH, or AA amyloid by immunofluorescence in 82% of cardiac specimens and 87% of renal specimens. In all cases, the amyloid classification was in good agreement with available clinical and laboratory assessments. A cross-study analysis of 163 cases of AL amyloidosis reveals probable systemic misdiagnosis of cardiac AL amyloidosis by the immunoperoxidase technique, but not by the immunofluorescence technique.
CONCLUSIONS: Amyloid deposits can be reliably subtyped in small diagnostic cardiac specimens using immunofluorescence. The practical aspects of implementing an immunofluorescence approach are compared with those of other approaches for subtyping amyloid in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18619857     DOI: 10.1016/j.carpath.2008.05.004

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  8 in total

1.  Abdominal subcutaneous fat pad aspiration and bone marrow examination for the diagnosis of AL amyloidosis: the reliability of immunohistochemistry.

Authors:  Kanji Miyazaki; Shigeo Kawai; Kenshi Suzuki
Journal:  Int J Hematol       Date:  2015-06-27       Impact factor: 2.490

2.  Optimization of Serum Immunoglobulin Free Light Chain Analysis for Subclassification of Cardiac Amyloidosis.

Authors:  Marc K Halushka; George Eng; A Bernard Collins; Daniel P Judge; Marc J Semigran; James R Stone
Journal:  J Cardiovasc Transl Res       Date:  2015-04-30       Impact factor: 4.132

3.  Amyloid in endomyocardial biopsies.

Authors:  Barbara Kieninger; Magdalena Eriksson; Reinhard Kandolf; Philipp A Schnabel; Stefan Schönland; Arnt V Kristen; Ute Hegenbart; Peter Lohse; Christoph Röcken
Journal:  Virchows Arch       Date:  2010-04-08       Impact factor: 4.064

Review 4.  Recent advances in the noninvasive strategies of cardiac amyloidosis.

Authors:  Lei Zhao; Quan Fang
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

5.  Direct tissue evaluation via immunofluorescence: in the diagnosis of hereditary transthyretin cardiac amyloidosis.

Authors:  Michael G Fradley; Joseph V Thakuria; A Bernard Collins; Stephanie A Moore; James R Stone
Journal:  Tex Heart Inst J       Date:  2012

Review 6.  Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021.

Authors:  M Hasib Sidiqi; Morie A Gertz
Journal:  Blood Cancer J       Date:  2021-05-15       Impact factor: 11.037

7.  Telocytes in human isolated atrial amyloidosis: ultrastructural remodelling.

Authors:  E Mandache; M Gherghiceanu; C Macarie; S Kostin; L M Popescu
Journal:  J Cell Mol Med       Date:  2010-12       Impact factor: 5.310

Review 8.  Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018.

Authors:  Morie A Gertz
Journal:  Blood Cancer J       Date:  2018-05-23       Impact factor: 11.037

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.